Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. sign the informed consent~2. Aged 20-70 years~3. ovarian cancer patients, staged IIIB - C or above~3) ASA I - II~Exclusion Criteria:~1. tranexamic acid allergy~2. pregnancy and lactation~3. only lymph node metastasise~4. history of mental disorder, immune system disorder~5. history of epilepsy, dyschromatopsia~6. arrhythmia~7. history of renal insufficiency~8. thrombosis related disease~9. Hb \< 90 g/dL~10. using anticoagulant drugs (not including aspirin discontinuation 1 week~11. having participated in other clinical trials, or refusing to join the research.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- high dose TXA (Type: EXPERIMENTAL): TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
- low dose TXA (Type: EXPERIMENTAL): TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
- normal saline (Type: PLACEBO_COMPARATOR): saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).